Objective: Pediatric studies for new biological agents are mandated by recent legislation, necessitating careful thought to evaluation of emerging multiple sclerosis (MS) therapies in children with MS. Challenges include a small patient population, the lack of prior randomized clinical trials, and ethical concerns. The goal of this meeting was to assess areas of consensus regarding clinical trial design and outcome measures among academic experts involved in pediatric MS care and research.
There are limited studies informing the use of disease-modifying treatments in children with multiple sclerosis (MS). 1 No therapies are approved for pediatric MS by the US Food and Drug Administration (FDA), and only limited interferon use in adolescents with MS has been approved by the European Medicines Agency (EMA). 1 As in adults, close to 40% of pediatric patients with MS discontinue treatment due to intolerance, toxicity, persisting relapses, or nonadherence, supporting the need for new therapeutic options in children. 2 Several new molecules have shown efficacy in phase III trials and could be available in the near future for adults with MS.
Recent legislation in the United States and Europe now mandates pediatric studies for new medicinal products. In Europe, a pediatric investigation plan (PIP) must be submitted to the EMA. Similarly, the Pediatric Research Equity Act (PREA) in the United States requires pediatric studies for any new active molecule, new dosage form, or new route of administration. A full or partial waiver is possible if the treated condition does not occur in the pediatric population or if studies are not feasible or appropriate or safe for the age group. Additionally, the Best Pharmaceuticals Act for Children (BPCA) in the United States provides for voluntary pediatric drug assessments via written requests issued by the FDA, with the incentive of eligibility of an additional 6 months of market exclusivity.
The International Pediatric MS Study Group (IPMSSG) is a voluntary group of over 150 academic physicians and researchers treating or studying MS in children convened under the auspices of the MS International Federation (MSIF). Details regarding its governance and structure are available on its Web site (www. ipmssg.org). The IPMSSG recently published a consensus statement endorsed by 50 of its members summarizing its views on evaluation of new and emerging therapeutics for MS in children. 1 Several challenges were identified in this initial consensus statement, which included the limited number of patients available for studies, the specifics of clinical trial design, and the implementation of planned studies. In order to address these issues, it was deemed necessary to hold a face-to-face meeting of key stakeholders including physicians treating children with MS, MS societies, and regulatory agency and pharmaceutical company representatives.
METHODS Meeting participants. A meeting was held on
January [19] [20] 2012 , in Washington, DC, sponsored by the US National MS Society (NMSS) and the MSIF. There were 69 meeting attendees including 25 IPMSSG members, of which 9 were from the IPMSSG Steering Committee, as well as 10 invited guests from the academic medical community with expertise in fields including biostatistical analysis, clinical trial design, MS therapeutics, MRI analysis in MS, and neuropsychology, a member of the Children's Oncology Group (COG), and a member of the pediatric rheumatology network. The academic experts (AEs) were identified by the IPMSSG Steering Committee for expertise in the listed fields. The list was ratified by the IPMSSG Secretariat. Representatives from the EMA, FDA, and Health Canada were in attendance. Representatives from each of the pharmaceutical companies with drugs that had completed phase II clinical trials as of August 2011 attended. Staff leadership from the NMSS, MSIF, MS Society of Canada, and the Italian MS Society participated.
Meeting agenda. Prior to the meeting, 7 workgroups of academic experts prepared summaries on the following: clinical outcome measures, clinical trial design, MRI outcome measures, cognitive outcome measures, pharmacokinetics, pharmacodynamics (safety and biological mechanisms), and long-term registries. A premeeting report was sent to participants 2 weeks before the meeting summarizing key items to be addressed and short summaries from each workgroup. On the first meeting day, IPMSSG members gave presentations reviewing the published IPMSSG therapeutics consensus statement, 1 current knowledge about the epidemiology and disease course of pediatric MS, and use of first-and second-line treatments in pediatric MS. The current chair of the COG network reviewed this organization's experience. Then, members from each workgroup presented summaries. Representatives from the pharmaceutical companies and regulatory agencies were also invited to present their views. The second day was dedicated to discussion of the points raised on the first day as well as identification of consensus points for the meeting report.
Meeting report logistics. All attendees were invited to participate in discussions. The report summarizes major areas of discussion, factual points, and areas of consensus achieved among the academic participants, henceforth termed "expert academic consensus." The consensus points listed reflect only the opinions of the academic participants and do not include those of the regulatory agencies or pharmaceutical companies that participated in the meeting. The representatives of the EMA, FDA, and Health Canada did not participate in any way in discussions regarding the number and sequence of proposed trials and were not present during these discussions.
IPMSSG survey. The IPMSSG Steering Committee administered a survey to its members 1 month after the meeting, which requested numbers of patients seen in the past 5 years, incidence of new patients seen in the past year, and opinions regarding points raised at the meeting. These responses are provided in Results.
RESULTS
The meeting focused on immunomodulatory therapies, since these are currently the most widely studied in MS. However, it was recognized that neuroprotective, remyelinating, or restorative therapies are forthcoming and require further discussion for consideration in the pediatric population.
There was consensus among the expert academic meeting attendees that the conduct of clinical trials of appropriate and safe therapies was important in the pediatric MS population for reasons summarized in table 1. The group identified several major challenges in the pediatric MS study design also summarized in table 1.
Precedents in other pediatric disorders. COG has had a pivotal role in transforming childhood cancer from a virtually incurable disease 50 years ago to a current combined 5-year survival rate of 80%. Development of COG Network for clinical-translational trials, including a Group Operation Center, Statistics and Data Center supported by the National Cancer Institute and over 200 member institutions, allowed the development of clinical trial protocols for childhood cancers including many rare disorders. Similar models have been employed for other rare pediatric disorders including cystic fibrosis and rheumatologic conditions in children.
AE consensus agreed implementation of COG model would significantly benefit clinical trials in pediatric MS. This model would include the identification of clinical trial sites, development of a centralized institutional review board, and development of formal advisory panels to regulatory agencies and pharmaceutical companies regarding the appropriateness, feasibility, optimal design, and implementation of clinical trials in pediatric MS.
Similarities and differences between pediatric and adult MS.
A key area of debate that emerged during the meeting was the extent of similarities and differences between pediatric and adult MS. This point is central in determining to what degree pediatric MS trial design may draw on a priori methodologies and results from adult MS clinical trials.
Studies following children within the first 2-5 years of disease demonstrated a higher frequency of clinical relapses 3 (annualized relapse rate [ARR] 0.9-1.4) compared to adults, as opposed to those with longer follow-up times (ARR 0.5-0.8) (table e-1 on the Neurology ® Web site at www.neurology.org). Compared to adult MS, children have an increased T2 lesion burden on MRI at disease onset 4,5 and frequent cognitive deficits 6, 7 in contrast with slower disability progression measured by the Expanded Disability Status Scale (EDSS). [8] [9] [10] [11] This information, obtained through cohort-based studies, suggests higher levels of inflammation in children. The AEs agreed that there was limited information regarding the underlying immunopathobiology of pediatric MS and the effects of the developing immune, nervous, and endocrine systems, which may lead to differentially expressed disease outcomes.
The AEs agreed that potential differences between adult and pediatric MS suggest that results obtained in adults cannot be directly extrapolated to children, and reinforce the need for controlled trials in children ensuring that the sample size for the relevant age population is large enough to obtain robust data.
Incidence and prevalence of pediatric MS. One of the major challenges in clinical trial planning is the low frequency of pediatric MS. The reported prevalence of pediatric MS differs among countries, with relatively frequent cases in Northern Europe, the United States, and Canada, and fewer cases reported from India, China, Japan, and Africa. Table 2 lists incidence studies of pediatric acute demyelinating syndrome (ADS) Patient populations. Current studies on relapse rates suggest higher rates early in the disease course; therefore, it may be important to restrict studies to patients within the first few years of disease in order to increase power. Twenty percent to 30% of patients with pediatric MS have onset before age 10. There was consensus among all except one AE attendee that children under the age of 10 should be included in therapeutic studies, particularly in pharmacokinetic (PK) and safety studies, since safe and effective dosing in young children is the most challenging to determine. Particular care should be taken in correctly diagnosing MS in young children, who may present differently compared to adolescents. 13, 14 Regulators expressed that in their view and given the change in the diagnostic criteria for adult MS, 15 studies in clinically isolated syndromes (CIS) in adults were not necessary since these 2 entities overlapped significantly. However, the AEs expressed that these criteria have yet to be comprehensively validated in children and that consensus regarding the identification of children with CIS likely to have or develop MS is required, since many do not develop MS.
Clinical trial outcome measures. Primary and secondary outcome measures have never been prospectively evaluated in therapeutic MS trials in children. Traditionally, relapse rate has been used as an outcome measure in adult MS studies. There was AE consensus that time to next relapse or annualized relapse rate should be used as a primary outcome measure in phase III trials. Time to next relapse after an initial attack of MS has been evaluated in a single report at a median of 1.1 year with 25% of the patients having a first relapse before 6 months. 16 Time to further relapses is not established. EDSS, frequently used for secondary endpoints in adult studies, is typically low in children with MS, 8 and is unlikely to change significantly in short-term trials. Novel scales and measures such as the 6-minute walk time are used in other diseases (i.e., neuromuscular disorders) but have to be validated in pediatric MS; thus no data allow current power calculations, and as such, these other outcome measures may not be considered as primary endpoints at present.
MRI outcome measures. Published MRI studies in pediatric MS have largely focused on defining the MRI features predictive of MS in children with CIS/ADS, or have analyzed associations with clinical outcomes. 9, 17 Two main issues were discussed: 1. The desirability of obtaining acceptance of MRI as a primary outcome. The AEs agreed that lesion accrual measured by MRI is an important outcome measure for clinical trials in children with MS. However, at present, regulatory opinion did not support MRI as a primary outcome measure in phase III studies in pediatric MS. Correlations between MRI features and longitudinal clinical outcomes may resolve this issue. Relationships between MRI measures and cognition have been demonstrated. 18, 19 Since accrual of physical disability is rarely observed in the pediatric age group, correlations between EDSS and MRI features may not be robust. Ongoing studies will clarify whether accrual of lesions in pediatric MS is an acceptable surrogate for clinical relapses in clinical trials. Using the number of cumulative new active lesions (CAL) in adult MS and assuming a similar behavior in pediatric MS, sample size for a phase II trial, which includes CAL at 4, 5, and 6 months as an endpoint, would require 50 patients in each group against placebo and 600 against active comparator. Consideration should be given to MRI as the primary endpoint in pediatric MS phase II trials and as a secondary endpoint in phase III trials, although further data are required on the rates of lesion accrual.
2. The best specific analysis suited for multicentric international trials. There was AE consensus that MRI analyses suited for clinical trials should rely on new lesion counts, rather than lesion volumes, to determine short-term disease activity. This is in part based on the occurrence of vanishing T2-bright lesions in very young patients. 13 Core metrics should include new T2 counts at a minimum and gadolinium-enhancing lesion counts if possible. All clinical trials in pediatric MS should employ high-quality standardized MRI protocols and centralized analyses. The ability to use sedation for children requiring it was discussed, although strategies to avoid sedation have been developed in several centers and may be considered for trials.
Advanced MRI metrics, including whole brain or regional brain region volumes, magnetization transfer ratio, diffusion tensor imaging, and cortical lesions, 5,18,20 United States Langer-Gould et al. 27 1.66/100,000 0.51/100,000
Abbreviations: ADS 5 acute demyelinating syndrome; MS 5 multiple sclerosis. a Estimated incidence.
were considered best suited as secondary or tertiary outcomes.
Cognitive outcomes. The consequences of MS in a developing brain and early cognitive dysfunction are major concerns that can be evaluated only in children and cannot be extrapolated from studies in adults. 6, 7, 21, 22 Cognitive function should be addressed in any therapeutic trial and requires the development of a core battery of neuropsychological tests applicable to international cross-sectional and longitudinal studies in pediatric MS. Challenges include differences in developmental trajectories and patterns of cognitive dysfunction in relation to patient age. Current research is limited by variable tools used by different research groups, preventing pooling of data across studies, and limited availability of validated assessment tools with satisfactory norms. 6, [21] [22] [23] Requirements for cognitive batteries to be used in pediatric MS clinical trials are listed in table 3. The AE-recommended core battery of 45 minutes duration and supplemental battery are detailed in table 4 with 1-year retest intervals on the basis of research in adults. Measures of fatigue, depression, and quality of life were also recommended in addition to cognitive assessment, although current information on the characteristics of different available assessment tools is insufficient to allow any specific recommendations.
Clinical trial design. AEs agreed that trials with a primary clinical endpoint, such as time to a new event or ARR, would translate more easily to clinical practice than phase II trials with MRI endpoints. MRI endpoints should, nevertheless, be included in pediatric MS trials as detailed in the MRI section. Clinical trials may take place in a phased approach with initial PK and dosefinding studies potentially combined in phase II studies and followed by definitive phase III studies.
Whether randomized controlled trials should use placebo or an active comparator was debated, since both strategies have advantages and challenges, summarized in table 5. In theory, placebo-controlled trials are ideal in the current environment as there are no approved treatments for pediatric MS, and placebo-controlled trials typically allow for smaller sample sizes than superiority trials (table e-2). However, this position may be difficult to accept because in some countries first-line disease-modifying therapies are commonly used off-label in pediatric MS.
The main problems with superiority trials include the need for large sample sizes and the issue of choosing Table 3 Requirements for cognitive batteries to be used in pediatric multiple sclerosis clinical trials an active comparator as none is approved for pediatric MS. Moreover, comparison to "active comparator," which itself has not been shown to be superior to placebo, may be uninformative. Use of Bayesian design incorporating a priori data from adult MS trials should lower the sample size required for trials, but would require the use of the same primary outcome measures and acceptance by regulatory agencies. AE consensus surrounding clinical trial design was that additional data regarding available patient numbers, acceptance of placebo-controlled trials by treating neurologists and families, and detailed phase III data from adult studies of potential agents to be evaluated are required to advise on the specifics of studies. Finally, AE consensus was that a long-term registry was required to provide relevant data on long-term safety.
Pharmacokinetics. To date, PK/pharmacodynamic studies have not been performed for any agent used in pediatric MS, and dosing recommendations are based purely on expert consensus. The workgroup discussed age-specific dosing requirements of medication, noting increased clearance of some drugs between 3 and 6 years of age and puberty. Lack of information regarding developmental profiles for hepatic and extrahepatic drug metabolizing enzymes may be an issue.
Feasibility regarding patient accrual and ethical concerns about exposures to unknown risks in children were discussed. Consequently, there was AE consensus about the need for predictive modeling, including 1) in silico techniques that provide simulations, or computer modeling of physically based PK/pharmacodynamic models, and 2) studies in juvenile animals to evaluate for safety. These methods may reduce the number of subjects required for PK studies.
Pharmacodynamics. The group agreed that all tolerability and safety issues identified in adult MS clinical trials and the ongoing postmarketing experience are relevant to pediatric MS. Additionally, there are particular concerns in pediatric populations with respect to immune maturity, immune repertoire, vaccine efficacy and safety, primary infection acquisition, and endocrine, musculoskeletal, and neurologic development as known side effects of drugs may be more pronounced or different in children. The group surmised that we should also learn from the experiences of other disciplines using immune-directed therapies in children (e.g., pediatric rheumatology, pediatric oncology).
Long-term drug safety registry. The AE consensus was that a single long-term drug safety registry focused on serious adverse events, development, and fertility should be used by all countries for all children with MS who have received or are receiving treatments in the context of clinical trials or off-label use, since children may be enrolled in more than one study during their childhood years and, most certainly, during their lifetime. A single registry is simpler, increases sample size, and ensures standardization of data collection. The registry can be either physician or patient (and parent) driven. Physician-driven registries can gather demographic and clinical information. Patient-driven databases can provide valuable information regarding quality of life as well as functional, emotional, and cognitive outcome. Data should be captured in a simple, user-friendly format.
An effective governance structure is important for maintaining a registry. Governance ensures the integrity of data collected, data analysis and quality control, and dissemination especially of serious adverse events. 10 Timing and implementation of clinical trials. At the time of the meeting, there were 8 approved PIPs posted on the EMA Web site. In addition, pediatric assessments under the PREA and written requests may be submitted under the BPCA act to the FDA. The AEs agreed that given the number of patients known to the IPMSSG who may be available for clinical trials, effective completion of only 1-2 studies with sample sizes of between 250 and 500 patients, each within a 2-to 3-year time period, is feasible. Such restrictions result in the need to prioritize trials for the most promising and safe therapies to evaluate. Development of methods to reduce sample sizes or trial duration, and still gain critical information to inform clinical practice and achieve regulatory approval, is crucial. Shorter, placebo-controlled trials may be acceptable to clinicians and families, provided that use of a placebo arm is coupled with stringent escape criteria such as offering standard of care treatment in the event of new disease activity. Use of MRI outcome measures may reduce the sample size required, since accrual of MRI lesions occurs more frequently than clinical relapses. Statistical modeling, including the use of Bayesian statistics to incorporate a priori data from adult trials or the identification and validation of more sensitive clinically relevant outcome measures, may reduce sample size. Trial designs should be explored in association with pharmaceutical companies and will have to satisfy regulatory requirements.
The IPMSSG endorses a collaborative effort for pediatric MS clinical trials. Dilution of effort through an "open market" approach will lead to insufficient enrollment in multiple concurrent clinical trials and failure to bring appropriate therapies to the pediatric population in a timely fashion. This would raise ethical concerns as it could unnecessarily expose patients to trial conditions and possible side effects without the benefit of gained knowledge. An alternate approach endorsed by the AEs at the meeting was the prioritization of the most promising agents for pediatric MS and a timely stepwise approach to initiating and completing these clinical trials. The elected Steering Committee of the IPMSSG expressed a strong interest in continuing to provide input on these issues through the incorporation of opinion from the larger IPMSSG membership, AEs, and patient groups. In addition, they expressed interest in continuing to provide information on demographic and clinical features of pediatric MS and study feasibility to the regulatory agencies and pharmaceutical companies and in working closely with industry to identify clinical trial sites, recruit patients for appropriate studies, and advise on clinical trial design (table 6 ).
Next steps. The Steering Committee of the IPMSSG laid out what it considers the next steps in the process of initiating appropriate clinical trials in a timely fashion: 1) ascertainment of clinicians and potential clinical trial sites; 2) informed evaluation of available therapies for study; 3) detailed discussions with expert panels regarding tailored clinical trial designs; and 4) continued interaction with regulators and pharmaceutical industry on the above points.
DISCUSSION Clinical trials in pediatric MS are an opportunity to gain well-defined PK, dosing, and efficacy data for appropriate therapies in this population and to allow children to benefit from the many advances in the MS field. The logistics of study design and clinical trial implementation require thoughtful and cooperative approaches from clinical, academic, and industry stakeholders. This meeting represents a first step in that process.
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